Spago Imaging AB (publ) announces company name change to Spago Nanomedical AB (publ)
At the Annual General Meeting on April 29th 2014, Spago Imaging AB (publ) decided to change the company name to Spago Nanomedical AB (publ). The new company name was registered on May 5th 2014 by the Swedish Companies Registration Office (Bolagsverket).
The name change will be registered in the trading system from May 7th 2014. The ticker symbol remains SPAG
For more information about the name change, contact
Andreas Bunge, CEO Spago Nanomedical AB, +46 708 242525.
Spago Nanomedical AB conducts development within nanomedicine with focus on cancer diagnostics and therapeutics. Operational focus is the development of the cancer selective MR contrast agent Spago Pix and the therapeutic project Tumorad for cancer selective radionuclide therapy. Both projects are based on the nanomedical platform IonXgel.
The goal of Spago Pix is to improve cancer diagnostics using magnetic resonance imaging (MRI) through earlier detection of tumors and metastases. Early detection improves possibilities for efficient treatment and patient survival. Tumorad is a further development of IonXgel aiming at delivering very low doses of radionuclides (radioactive isotopes) for local radiation treatment.